PLATINUM: Post-ablation Alcohol Impacts Arrhythmia Recurrence, Quality of Life and Cognition in AF

Sponsor
Texas Cardiac Arrhythmia Research Foundation (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05510167
Collaborator
(none)
130
2
35.3

Study Details

Study Description

Brief Summary

Earlier studies have shown a dose-dependent relationship between alcohol intake and incident atrial fibrillation (AF) as well as a causal link with several risk factors for AF such as hypertension, obesity and sleep apnea. However, the effect of drinking (alcohol) on post-ablation outcome such as arrhythmia recurrence, quality of life (QoL) and cognitive function in AF patients is unclear. Therefore, we aim to find the answer for a very frequently asked question, "is it safe to continue drinking alcohol (at the pre-ablation level) following catheter ablation OR should the intake be reduced for better outcome?", in this randomized trial.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Study arm
N/A

Detailed Description

  1. BACKGROUND Earlier studies have not only reported alcohol-abstinence to be associated with lower recurrence of AF in patients receiving non-ablative antiarrhythmic therapy, but also unfavorable outcome among regular drinkers (high frequency and quantity) compared to non-drinkers undergoing AF ablation (1-3). In a meta-analysis of 14 studies, where the effect measures for AF associated with highest vs lowest alcohol intake were pooled for analysis, not consuming alcohol was observed to be the most favorable in terms of AF risk reduction (4). Larsson et al reported alcohol drinking, even in moderate quantity, to be a risk factor for incident AF, whereas Zhang et al observed moderate drinking to be associated with high AF risk in men only and not in females (5, 6). Moreover, a causal link between alcohol intake and other cardiovascular morbidities such as obesity, hypertension, left ventricular dysfunction and sleep apnea that are known risk factors for AF has been documented by several studies (1). Thus, we know that alcohol consumption, even in moderate quantity, increases the risk for AF, although may not be across genders. Observational studies also have shown unfavorable procedure outcome to be more common in drinkers compared to non-drinkers receiving AF ablation. However, there is no randomized data to support the latter statement. Additionally, there are no data on the influence of alcohol intake on the cognitive function and QoL in AF patients receiving catheter ablation. Therefore, this investigator-initiated, randomized trial has been designed to examine the impact of alcohol intake vs abstinence on arrhythmia recurrence and burden, QoL and cognitive function in regular drinkers undergoing their first catheter ablation.

  2. STUDY RATIONALE We hypothesize that alcohol-abstinence will significantly improve the procedural outcome, QoL and cognitive function in the study population compared to the non-abstinence cohort.

  3. STUDY OBJECTIVES Primary Objective Arrhythmia recurrence across all AF types at 8 months after the ablation procedure, off- or on-antiarrhythmic drug (AAD) Secondary Objective

  1. Change in QoL score measured by AFEQT survey at baseline and 6 months 2) Change in cognitive function measured by MoCA survey 3) Arrhythmia burden at follow-up

Study period will start from the day after the procedure and continue for 8 months (2-month blanking period+ 6 months follow-up).

Group 1: Complete abstinence or ≤2 drinks/week in group 1 during the study period Group 2:

Allowed to continue their pre-ablation drinking habit

Study Design

Study Type:
Interventional
Anticipated Enrollment :
130 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Paroxysmal and Persistent AF patients undergoing their first catheter ablation will be screened for eligibility and those that meet the criteria and consent to participate will be randomly assigned to group 1 or 2. Study period will start from the day after the procedure and continue for 8 months (2-month blanking period+ 6 months follow-up). Group 1: Complete abstinence or ≤2 drinks/week in group 1 during the study period Group 2: Allowed to continue their pre-ablation drinking habitParoxysmal and Persistent AF patients undergoing their first catheter ablation will be screened for eligibility and those that meet the criteria and consent to participate will be randomly assigned to group 1 or 2. Study period will start from the day after the procedure and continue for 8 months (2-month blanking period+ 6 months follow-up). Group 1: Complete abstinence or ≤2 drinks/week in group 1 during the study period Group 2: Allowed to continue their pre-ablation drinking habit
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Impact of Post-ablation Alcohol Intake on Arrhythmia Recurrence, Quality of Life and Cognition in Patients With Atrial Fibrillation
Anticipated Study Start Date :
Aug 22, 2022
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Aug 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Study

Complete abstinence or ≤2 drinks/week in group 1 during the study period

Behavioral: Study arm
Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation

Active Comparator: Control

Allowed to continue their pre-ablation drinking habit

Behavioral: Study arm
Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation

Outcome Measures

Primary Outcome Measures

  1. Arrhythmia recurrence [8 months after the ablation procedure for AF]

    Arrhythmia recurrence across all AF types at 8 months after the ablation procedure, off- or on-antiarrhythmic drug (AAD)

Secondary Outcome Measures

  1. Change in QoL [6 months after the blanking period of 2 months]

    Change in QoL measured by AFEQT survey at baseline and 6 months

  2. Change in cognitive function [6 months after the blanking period of 2 months]

    Change in cognitive function measured by MoCA survey

  3. Arrhythmia burden [6-8 months following ablation]

    Arrhythmia burden at follow-up

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • AF patients that regularly consume >5 alcoholic drink (*12 g of pure alcohol/drink)/week

  • Paroxysmal or persistent AF

  • First catheter ablation History of alcohol-induced arrhythmia

  • Willing to sign the written informed consent

Exclusion Criteria:
  • Binge drinkers (alcohol dependence)

  • Non-drinkers

  • LVEF <35%

  • Psychiatric conditions

  • MoCA score ≤ 17 on Montreal Cognitive Assessment (MoCA)

  • Patients with established dementia

  • Medically unstable patients (acute/unstable or poorly controlled problems that would demand focused, relatively urgent or emergent medical attention)

  • Unwilling for alcohol-abstinence

  • Long-standing persistence AF

  • Patient under legal protection

  • Pregnancy

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Texas Cardiac Arrhythmia Research Foundation

Investigators

  • Principal Investigator: Andrea Natale, Texas Cardiac Arrhythmia Institute, St.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Andrea Natale, Executive Medical Director, Texas Cardiac Arrhythmia Research Foundation
ClinicalTrials.gov Identifier:
NCT05510167
Other Study ID Numbers:
  • TCAI
First Posted:
Aug 22, 2022
Last Update Posted:
Aug 22, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Andrea Natale, Executive Medical Director, Texas Cardiac Arrhythmia Research Foundation
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2022